Sunday
09.22.2019
12:49 PM
Login form
Search
Calendar
«  May 2013  »
SuMoTuWeThFrSa
   1234
567891011
12131415161718
19202122232425
262728293031
Entries archive

My site

Main » 2013 » May » 26
Rapid PC Plus Transformation and Effective Cost Control Drive 90 Percent Profit Growth in Q4

HONG KONG - Saturday, May 25th 2013 [ME NewsWire]

    Records in annual pre-tax income of US$801 million and earnings of US$635 million
    Record annual sales of US$34 billion
    Record 52.4 million PC shipments and record 15.5 percent global market share
    Full year basic EPS of 6.16 US cents, or 47.78 HK cents
    Net cash reserves of US$3.1 billion (as of March 31, 2013)

(BUSINESS WIRE)-- Lenovo Group today announced results for its fourth fiscal quarter and full-year ended March 31, 2013. With record full-year sales of US$34 billion, an increase of 15 percent year-over-year, a record full-year pre-tax income of US$801 million, up 38 percent year-over-year and record earnings of US$635 million, up 34 percent, Lenovo had a strong showing. While Lenovo continued to close in on the # ... Read more »
Views: 83 | Added by: uaeonlinenews | Date: 05.26.2013

ME Newswire / Business Wire

BOUDRY, Switzerland - Saturday, May 25th 2013

European Medicines Agency Accepts Regulatory Submission of Type II Variation for ABRAXANE for the Treatment of Advanced Pancreatic Cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation (Celgene) (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) for the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first–line treatment of patients with advanced pancreatic cancer.

The FDA grants Priority Review to medicines that, if approved, have the potential to offer significant improvement compared to marketed products or provide a treatment where no adequate therapy exists. The goal for completing a Priority Review is six months. The Prescription Drug User Fee Act (PDUFA) ... Read more »
Views: 117 | Added by: uaeonlinenews | Date: 05.26.2013